Liver Biomarkers in Anorexia Nervosa

Nantes University Hospital50 enrolled

Overview

The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.

Prevalence of hepatic fibrosis will be non-invasively investigated, in the Anorexia Nervosa inpatient population, using the Fibroscan ®. Furthermore, liver blood markers will be assessed.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Anorexia Nervosa

Interventions

FibroscanDIAGNOSTIC_TEST

Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.

Eligibility

Sex: ALLMin age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria : * Patient over 15 years old * Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Admission to the endocrinology, diabetology and nutrition department of the Nantes University Hospital. Exclusion Criteria : * Chronic active viral hepatitis * Hemochromatosis * Other genetic, autoimmune, toxic or drug-induced hepatitis * Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months * Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)

Locations (1)

Nantes University Hospital

Nantes, Loire-Atlantique, France

RECRUITING

Outcomes

Primary Outcomes

Liver fibrosis prevalence in patients with Anorexia nervosa

Liver stiffness will be assessed using Fibroscan (kPA) within the 24 hours following admission to the endocrinology, diabetology and nutrition department.

Time frame: Day one

Central Contacts

Sarra SMATI-GRANGEON, PH

CONTACT

33 2.53.48.27.01 sarra.grangeon@chu-nantes.fr

An THYS, PH

CONTACT

33 2.53.48.27.06 an.thys@chu-nantes.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.